Novartis AG (NVS): Price and Financial Metrics


Novartis AG (NVS)

Today's Latest Price: $96.29 USD

0.93 (-0.96%)

Updated Feb 20 8:04pm

Add NVS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVS Stock Summary

  • Novartis Ag's market capitalization of $218,636,817,183 is ahead of 99.35% of US-listed equities.
  • With a year-over-year growth in debt of 57.5%, Novartis Ag's debt growth rate surpasses 79.84% of about US stocks.
  • The volatility of Novartis Ag's share price is greater than that of only 7.11% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to NVS, based on their financial statements, market capitalization, and price volatility, are CSCO, PFE, MRK, RDS.A, and ORCL.
  • Visit NVS's SEC page to see the company's official filings. To visit the company's web site, go to www.novartis.com.
NVS Daily Price Range
NVS 52-Week Price Range

NVS Stock Price Chart More Charts


NVS Price/Volume Stats

Current price $96.29 52-week high $99.84
Prev. close $97.22 52-week low $74.97
Day low $95.88 Volume 1,283,400
Day high $97.09 Avg. volume 1,829,776
50-day MA $95.05 Dividend yield 1.89%
200-day MA $90.18 Market Cap 220.68B

Novartis AG (NVS) Company Bio


Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.

NVS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$96.29$52.23 -47%

Below please find a table outlining a discounted cash flow forecast for NVS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Novartis Ag ranked in the 39st percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 46.33%. As for the metrics that stood out in our discounted cash flow analysis of Novartis Ag, consider:

  • NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 39.16% of tickers in our DCF set.
  • The weighted average cost of capital for the company is 8. This value is greater than just 22.18% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-48%
1%-47%
2%-47%
3%-46%
4%-45%
5%-45%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVS, try GSK, MCK, SYNH, HRC, and IONS.


NVS Latest News Stream


Event/Time News Detail
Loading, please wait...

NVS Latest Social Stream


Loading social stream, please wait...

View Full NVS Social Stream

NVS Price Returns

1-mo 1.13%
3-mo 6.42%
6-mo 8.88%
1-year 23.43%
3-year 54.93%
5-year 23.55%
YTD 1.69%
2019 28.03%
2018 5.95%
2017 18.80%
2016 -12.56%
2015 -4.52%

NVS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVS Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.6415 seconds.